Agha M et al. Efficacy and safety of the BCMA-directed CAR-T therapy, ciltacabtagene autoleucel, in patients with progressive multiple myeloma after 1-3 prior lines of therapy: Initial results form CARTITUDE-2. EHA 2021;Abstract S190.
Bahlis NJ et al. Efficacy and safety of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MM). ASCO 2021;Abstract 8006.
Berdeja JG et al. Updated results of a phase 1, first-in-human study of talquetamab, a G protein-coupled receptor family C group 5 member D (GPRC5D) × CD3 bispecific antibody, in relapsed/refractory multiple myeloma (MM). ASCO 2021;Abstract 8008.
Einsele H et al. Biological correlative analyses and updated clinical data of ciltacabtagene autoleucel (clita-cel), a BCMA-directed CAR-T therapy, in lenalidomide (len)-refractory patients (pts) with progressive multiple myeloma (MM) after 1-3 prior lines of therapy (LOT): CARTITUDE-2, cohort A. ASCO 2022;Abstract 8020.
Lonial S et al. Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study. Cancer 2021;127(22):4198-212. Abstract
Lonial S et al. Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM). Blood Cancer J 2021;11(5):103. Abstract
Lonial S et al. Safety and clinical activity of belantamab mafodotin with lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM): DREAMM-6 arm-A interim analysis. SOHO 2022;Abstract MM-459.
Lonial S et al. Synergistic effects of low-dose belantamab mafodotin in combination with a gamma-secretase inhibitor (nirogacestat) in patients with replased/refractory multiple myeloma (RRMM): DREAMM-5 study. ASCO 2022;Abstract 8019.
Martin T et al. Ciltacabtagene autoleucel, an anti–B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J Clin Oncol 2022;[Online ahead of print]. Abstract
Mateos MV et al. MajesTEC-3: Randomized, phase 3 study of teclistamab plus daratumumab versus investigator’s choice of daratumumab, pomalidomide, and dexamethasone or daratumumab, bortezomib, and dexamethasone in patients with relapsed/refractory multiple myeloma. ASCO 2022;Abstract TPS8072.
Moreau P et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med 2022;387(6):495-505. Abstract
Nooka AK et al. Teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM): Updated efficacy and safety results from MajesTEC-1. ASCO 2022;Abstract 8007.
O’Donnell EK et al. Quality of life, psychological distress, and prognostic awareness in patients with multiple myeloma. ASH 2021;Abstract 4082.
O’Donnel EK et al. Quality of life, psychological distress, and prognostic perceptions in patients with multiple myeloma. Cancer 2022;128(10):1996-2004. Abstract
Quach H et al. Safety and clinical activity of belantamab mafodotin with lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM): DREAMM-6 arm-A interim analysis.ASCO 2022;Abstract 8017.
Raje NS et al. Updated clinical and correlative results from the phase I CRB-402 study of the BCMA-targeted CAR T cell therapy bb21217 in patients with relapsed and refractory multiple myeloma. ASH 2021;Abstract 548.
Suvannasankha A et al. Safety and clinical activity of belantamab mafodotin with pembrolizumab in patients with relapsed/refractory multiple myeloma (RRMM): DREAMM-4 study. EHA 2022;Abstract P940.
Terpos E et al. Safety and efficacy of belantamab mafodotin in combination with RD in newly diagnosed, transplant ineligible multiple myeloma patients: A phase 1/2 study by the Hellenic Society of Hematology. EHA 2022;Abstract S178.
Usmani SZ et al. DREAMM-9: Phase I study of belantamab mafodotin plus standard of care in patients with transplant-ineligible newly diagnosed multiple myeloma. EHA 2022;Abstract P942.
Usmani SZ et al. Phase 1b/2 study of ciltacabtagene autoleucel, a BCMA-directed CAR-T cell therapy, in patients with relapsed/refractory multiple myeloma (CARTITUDE-1): Two years post-LPI. ASCO 2022;Abstract 8028.
Usmani SZ et al. Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): A multicentre, open-label, single-arm, phase 1 study. Lancet 2021;398(10301):665-74. Abstract
van de Donk NWCJ et al. Biological correlative analyses and updated clinical data of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR-T therapy, in patients with multiple myeloma (MM) and early relapse after initial therapy: CARTITUDE-2, cohort B. ASCO 2022;Abstract 8029.
Zonder JA et al. LINKER-MM1 — Early, deep, and durable responses, and low rates of cytokine release syndrome with REGN5458, a BCMA x CD3 bispecific antibody, in a phase 1/2 study in patients with relapsed/refractory multiple myeloma. iMSM 2022;Abstract OAB-056.